NOVO NORDISK A/S Bagsværd, Denmark, 9 May 2023 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 5.8 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares will be repurchased during the trading period starting 10 May 2023 and ending on 8 August 2023. A maximum of 190,000,000 B shares in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.
Contact for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Natalia Salomao Abrahao (US) +1 848 304 1027 niaa@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
Company announcement No 33 / 2023
Attachment
- CA230509-2-Share-repurchase-initiation
